<DOC>
	<DOC>NCT02396069</DOC>
	<brief_summary>Double blind, randomized, placebo control, multiple dose, dose escalation study</brief_summary>
	<brief_title>The Evaluation of Safety, Tolerability and Pharmacokinetics/Pharmacodynamics of JPI-289 in Healthy Male Volunteers</brief_title>
	<detailed_description>A phase I clinical study, randomized, double-blind, placebo-controlled, multiple doses, dose escalation study of the safety, tolerability and pharmacokinetics/pharmacodynamics of JPI-289 in healthy male volunteers.</detailed_description>
	<criteria>19~55 years healthy male BMI measurement 20kg/m²~27kg/m² 90 ≤ SBP＜140(mmHg) 60 ≤ DBP＜100(mmHg) 45 ≤ Pulse rate＜100(bpm) Signed the informed consent form to participate voluntarily and to comply with the trial requirements For a followup visit and during the study period, blood samples and availability History of clinically significant hepatic, gastrointestinal, pulmonary, musculoskeletal, endocrine, psychiatric, hematooncologic, cardiovascular (Specially asthma, obstructive pulmonary disease, peptic ulcer) History of skin disease of graft affecting absorption of the drug History of drug abuse Positive urine drug screening Administrated investigational product in a previous clinical trial within 60 days of the screening test Donated blood within 60 days prior to screening test</criteria>
	<gender>Male</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>